Geron Corporation (GERN)
- Previous Close
1.3200 - Open
1.3000 - Bid 1.1700 x 100
- Ask 1.3500 x 900
- Day's Range
1.2700 - 1.4400 - 52 Week Range
1.1700 - 5.3400 - Volume
14,245,545 - Avg. Volume
15,618,073 - Market Cap (intraday)
856.648M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.12
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
www.geron.comRecent News: GERN
View MorePerformance Overview: GERN
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GERN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GERN
View MoreValuation Measures
Market Cap
840.72M
Enterprise Value
555.87M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.08
Price/Book (mrq)
3.00
Enterprise Value/Revenue
7.22
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-226.73%
Return on Assets (ttm)
-21.98%
Return on Equity (ttm)
-66.09%
Revenue (ttm)
76.99M
Net Income Avi to Common (ttm)
-174.57M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
406.57M
Total Debt/Equity (mrq)
43.42%
Levered Free Cash Flow (ttm)
-137.23M